<DOC>
	<DOCNO>NCT00003096</DOCNO>
	<brief_summary>RATIONALE : Analyzing number structure gene find child 's cancer cell may help doctor improve method diagnose treat child brain tumor . PURPOSE : This clinical trial study number structure gene cancer cell child brain tumor .</brief_summary>
	<brief_title>Gene Testing Help Diagnosis Treatment Childhood Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine chromosomal gain loss DNA ploidy analysis comparative genomic hybridization patient primitive neuroectodermal tumor medulloblastomas . - Determine frequency specific chromosomal abnormality , include deletion chromosomal region 6 , 17 , 22 , patient . - Perform statistical analysis determine possible association chromosomal abnormality DNA ploidy patient age , tumor histology , tumor location , extent disease , event-free survival . OUTLINE : DNA ploidy analysis perform determine overall level aneuploidy . The result compare comparative genomic hybridization ( CGH ) analysis , use demonstrate tumor-specific loss gain , include amplification , specific chromosomal region . Tumors also screen specific abnormality fluorescent situ hybridization ( FISH ) , detect chromosomal rearrangement , include balanced translocation , deletion , amplification , etc . PCR-based microsatellite polymorphism analysis may also perform . Primitive neuroectodermal tumor ( PNETs ) screen FISH distal 17p13.3 cosmid 17q25 cosmid identify tumor 17p deletion . Atypical teratoid/rhabdoid tumor PNETs without 17p deletion screen FISH series cosmid 22q11.2 . PNETs also screen interphase FISH cosmid chromosome 6 identify tumor deletion . Patients receive result genetic test result influence type duration treatment . PROJECTED ACCRUAL : This study accrue 360 specimen .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary CNS malignancy consistent primitive neuroectodermal tumor , medulloblastoma , atypical teratoid/rhabdoid tumor Must enter CCG9921 , CCG9931 , CCGA9961 , CCG99703 frontline study develop CCG90024 CCG90025 Retrospective specimen also obtain CCG921 , CCG923 , CCG9892 , CCG9921 , CCG9931 PATIENT CHARACTERISTICS : Age : Under 21 Performance status : See Disease Characteristics Life expectancy : See Disease Characteristics Hematopoietic : See Disease Characteristics Hepatic : See Disease Characteristics Renal : See Disease Characteristics PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
</DOC>